Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Inhibitors of Bruton’s tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who were either treatment-naïve (TN) or had relapsed/refr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Trotman, Judith, Opat, Stephen, Gottlieb, David, Simpson, David, Marlton, Paula, Cull, Gavin, Munoz, Javier, Tedeschi, Alessandra, Roberts, Andrew W., Seymour, John F., Atwal, Siminder Kaur, Yu, Yiling, Novotny, William, Holmgren, Eric, Tan, Ziwen, Hilger, James D., Huang, Jane, Tam, Constantine S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596846/
https://ncbi.nlm.nih.gov/pubmed/32698195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados